Low-dose-rate brachytherapy boost (LDR-PB) achieves better rates of biochemically disease-free outcomes in prostate cancer.
Adding short-term androgen deprivation therapy to radiotherapy does not improve overall survival in intermediate-risk prostate cancer.
Adding bicalutamide improves overall survival among patients with advanced nonmetastatic hormone-naïve prostate cancer.
Cancer-specific and overall survival is decreased in men with intermediate-risk versus low-risk tumors.
Researchers observed a significant 36% decreased overall and prostate cancer-specific mortality.
The 4Kscore enables better identification of men who harbor high-grade prostate cancer.
The 5-year risk of overall mortality is decreased by 50% compared with androgen deprivation therapy alone.
This medication sequence was associated with longer progression-free and overall survival compared with the reverse.
Researchers found elevated familial risks for testicular, prostate, bladder, and kidney cancers.
Prostate cancer progression was delayed by a median 10 months in statin users.
A history of testicular cancer was associated with a greater likelihood of prostate cancer overall and intermediate- or high-risk disease.
No higher risk of adverse pathology among men on active surveillance who delayed surgery until signs of disease progression.
The proportion of men diagnosed with intermediate- or high-risk disease rose 6% from 2011 to 2013, study finds.
Risk factors include male gender, distant disease, increasing age, race/ethnicity
Research raises concerns about possible overuse of radiation therapy
Sexual function declines for both men and women following radical prostatectomy, but some aspects of care may help couples.
From 2004 to 2009, there was a marked increase in observation (watchful waiting and active surveillance) among men with low-risk prostate cancer.
Variation exists at a high-volume center when selecting patients with low-risk prostate cancer for prostatectomy.
Guideline outlines recommended follow-up care for prostate cancer survivors
Just over 41% of patients eligible for active surveillance by European standards were found to have undergraded prostate cancer.
Focal and whole-gland approaches may provide alternatives for recurrent PCa after radiotherapy
Patients who received the drug as part of their treatment survived longer than those on placebo by a median 4.4 months.
Researchers find no increased risk of adverse pathologic outcomes among men who put off radical prostatectomy for up to 12 months.
Patients with hemophilia, however, do have a higher incidence of cancers overall.
Men who take phosphodiesterase type 5 inhibitors after radical prostatectomy are more likely to experience biochemical recurrence of disease.
Former, as well as current, smokers saw higher risk for radiation treatment-related urinary side effects.
Magnetic resonance imaging technology with ultrasound found 30% more high-risk prostate cancers and 17% fewer low-risk cancers.
- Prepping Your Practice for Retirement
- Support for Adjuvant Chemotherapy in Nonmetastatic Bladder Cancer
- Low-dose Brachytherapy Provides Better Outcomes in Intermediate PCa
- Short-Term ADT+Radiotherapy Does Not Help Intermediate PCa Survival
- Early Bicalutamide Aids Survival in Nonmetastatic Prostate Cancer
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)